SCHEMBL16748447

SCHEMBL16748447

Nc1nc(Nc2ccc(Br)cc2)nc(-n2c(C3CC3)nc3c(F)cccc32)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 7/20 0.35
ALDH1A1 P00352 4/20 0.34
MAPT P10636 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
AGPAT2 O15120 1/20 0.34
USP2 O75604 1/20 0.34
HTT P42858 1/20 0.34
SLC29A2 Q14542 1/20 0.33
SLC29A1 Q99808 1/20 0.33
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KDM4E B2RXH2 1/20 0.32
BLM P54132 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP11B2 P19099 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
PABPC1 P11940 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748596 0.90 MAPK1 (0.38) BMI1ALDH1A1MAPTTDP1AGPAT2
SCHEMBL16740853 0.90 HTT (0.43) BMI1ALDH1A1MAPTTDP1USP2
SCHEMBL16748499 0.89 BMI1 (0.47) BMI1MAPTLMNA
SCHEMBL16740797 0.88 BMI1 (0.47) BMI1ALDH1A1MAPTSLC29A2SLC29A1
SCHEMBL16748502 0.86 BMI1 (0.49) BMI1MAPTSLC29A2SLC29A1IDH1
SCHEMBL16748449 0.84 AGPAT2 (0.40) BMI1ALDH1A1MAPTTDP1AGPAT2
SCHEMBL16740711 0.84 BMI1 (0.47) BMI1MAPTAGPAT2HPGDNPSR1
SCHEMBL16740819 0.82 BMI1 (0.38) BMI1ALDH1A1USP2GAAHPGD
SCHEMBL16740729 0.81 AGPAT2 (0.39) BMI1ALDH1A1MAPTTDP1AGPAT2
SCHEMBL16748448 0.80 BMI1 (0.42) BMI1ALDH1A1MAPTTDP1AGPAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885ALDH1A1 1740/4885MAPT 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.